August 27, 2026
It’s time to see who’s right
Back on April 16th Abbott CEO Robert Ford stated-
“You are going to have about 5 million SGLT2 users that are not using the product who will now benefit from having continuous ketone monitoring. “
Now that the FDA has approved the Libre Duo we’re about to find out who's right Robert or I. The general consensus among most in the diabetes community is the Duo provides a data point which is not valued or understood by the majority of patients, this includes the 5 million on SGLT2. There is a minority that believe this is a . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.
